Organized by Natera

Description

Molecular insights help inform changes in practice that can impact patient care on a large scale. The Trifecta Study results will be presented by Dr. Philip Halloran from the Alberta Transplant Applied Genomics Centre (ATAGC) in Alberta, Canada. The Trifecta study analyzed a biopsy-matched kidney transplant cohort using both molecular microscopy and histology and showed the combination of dd-cfDNA fraction and estimated quantity was significantly more predictive for rejection than either variable alone. Next, Dr. Reza Motallebzadeh from the UCL Institute of Immunity & Transplantation in London will talk about the importance of an individualized IS regimen and using Prospera as a tool to achieve this goal. Later, Dr. Phil Gauthier, our lead Sr. Medical Director, will talk about innovations in kidney care using Renasight, a comprehensive genetic panel.